80062256 - Management of the Lung Nodule for the Primary Care Provider: Lung Cancer Screening to Lung Cancer

Friday, November 10, 2023, 8:00 AM - 5:00 PM, Albert H. Owens Auditorium, Koch Cancer Research Building, Baltimore, MD, Baltimore, MD

Attendance is available in person or virtually. Please select the appropriate registration type when registering.

 

Lung cancer is the leading cause of cancer death in the United States, with an estimated 238,340 new diagnoses of lung cancer in 2023 resulting in more than 127,070 deaths, making lung cancer more deadly than breast, prostate and colon cancer combined. Although the number of new cases of lung cancer is declining, the death rate from lung cancer continues to be staggering. Among new diagnoses in the United States, approximately 40% occur in current smokers, 40% in former smokers, and 20% in patients who have never smoked. Difficulties faced in the treatment of lung cancer are compounded by the frequent late stage of diagnosis in combination with associated environmental and genetic factors. Despite evidence that lung cancer screening using low dose CT scans is beneficial and can shift the trend from later to earlier stage disease at time of diagnosis, only ~6% of the country’s eligible population is being screened for lung cancer. Recent advances in lung cancer research have provided improved understanding and stratification of different types of non-small-cell lung cancer. This has led to further research which has and continues to identify targetable molecular and genetic mutations as well as biomarkers of immunotherapeutics. As our knowledge improves, the previous practice to treat all non-small-cell lung cancer with cytotoxic chemotherapeutic agents has undergone immense change. We are now entering an era of personalized therapy in which lung cancer is characterized by specific potentially targetable genetic alterations and biomarkers to immunotherapy. Recognizing these targets, developing and testing targeted chemotherapeutics, evaluating mechanisms of tumor resistance and suitability for immunotherapy require a multi-disciplinary approach and collaborative efforts. At the center of care remains the general practitioner who is often faced with fielding most questions and is responsible for knowing who to screen and when to refer to a subspecialist. This activity is designed to ensure that we continue to move the needle for positive outcomes in lung cancer by addressing common questions and providing the latest updates on personalized therapies so that primary providers are knowledgeable and comfortable with lung cancer screening, answering patient queries, knowing when to refer and what to expect when their patients have lung cancer.

1. Discern the patient selection criteria for lung cancer screening.
2. Describe the appropriate selection of diagnostic modalities in the work-up of a patient with suspected lung cancer.
3. Identify and describe updates and advances in chemotherapy treatment for patients with advanced lung cancer.
4. Discuss new advances in immunotherapy in the treatment of lung cancer.
5. Evaluate patients with newly diagnosed lung nodules.

Friday, November 10, 2023, 7:30 AM ET  

Virtual Learners should log in and test their zoom connection by 7:15 EST.  

FEES
Methods of Payment:  Learners must register and submit full payment prior to the start of the activity.  On-site payments can only be accepted if made by learners via credit card through the online portal by 5:00 p.m. ET on the first day of the activity. The registration fee for in-person learners includes instructional materials, continental breakfast, refreshment breaks, lunch and access to visit exhibit booths. The registration fee for virtual learners includes instructional materials and online access via Zoom during conference hours. Due to additional expenses and guarantees, transfer between in-person attendance to virtual attendance is not possible should you decide to change your registration type within 48 hours (November 7th 5:00 p.m. EST).

In-Person Registration Type:

Physicians................................................................................... $295.00 
Nurses/NPs/PAs/Allied Health Professionals......... $100.00 

Virtual Attendance Registration Type:

Physicians................................................................................... $275.00 
Nurses/NPs/PAs/Allied Health Professionals......... $75.00 

Please indicate your registration type when registering.  

 

LATE FEE AND REFUND POLICY  

A $50 late fee applies to registrations received after 5:00 p.m. ET on Tuesday, November 7, 2023.  A handling fee of $50 will be deducted for cancellation.  An additional fee may apply for cancellation of other events, including workshops and social activities.  Refund requests must be received by fax or mail by Tuesday, November 7, 2023. No refunds will be made thereafter. Transfer of registration to another Johns Hopkins activity in lieu of cancellation is not possible.  

ACCREDITATION STATEMENT 

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

The Johns Hopkins School of Medicine takes responsibility for the content, quality and scientific integrity of this CME activity.

CREDIT DESIGNATION STATEMENT 
The Johns Hopkins University School of Medicine designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) Program 
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) medical knowledge program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

OTHER CREDITS
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. 

PAs may claim a maximum of 7.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

The Johns Hopkins University has approved this activity for 7.75 contact hours for non-physicians.  

POLICY ON PRESENTER AND PROVIDER DISCLOSURE 
It is the policy of the Johns Hopkins School of Medicine that the presenter and provider globally disclose conflicts of interest. The Johns Hopkins School of Medicine OCME has established policies in place to identify and mitigate relevant conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.

Mitigation of Relevant Financial Relationships

Johns Hopkins University adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Friday, November 10, 2023